Pharmacies and State Boards Now Decide Who Gets Fall Shots

Four U.S. doctor groups posted updated flu and COVID vaccine recommendations on Sept. 2, 2026. The chart is clear. Getting the shot still depends on a pharmacist, a state board, an FDA label, and a CDC panel stuck in court.

Flu clinics are already open, and 2026-27 COVID-19 doses are arriving after late-August approvals. RSV protection for infants and older adults is in the same season. Patients who walk in with the new society advice can still be told the label, the standing order, or the insurer says something else.

Four Medical Groups Issued Shared Fall Shot Advice

The American Academy of Family Physicians, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America each put out guidance for their own patients. They coordinated through the Vaccine Integrity Project at the University of Minnesota, which published companion evidence reviews the same day. The American Medical Association posted a consolidated flu, COVID and RSV chart so a clinic can print one page instead of four PDFs.

Dr. Sandra Fryhofer of the AMA said there has been “a lot of confusion and chaos regarding vaccine recommendations,” and that the posted evidence is meant to give “clear, consistent, science-based guidance even while the federal process is in flux.” The AAFP, which represents 124,500 family physicians and students, put the same point in plainer clinic language.

Vaccines are one of medicine’s greatest success stories. They prevent serious illness, reduce hospitalizations and long-term complications and save lives. As federal guidance evolves, the science behind vaccines remains strong.

Dr. Sarah Nosal, President, American Academy of Family Physicians, Sept. 2, 2026 release

The family physicians’ fall immunization recommendations say all adults 19 and older should get a COVID-19 shot, with extra weight on ages 65 and up, people at higher risk, and anyone who has never had one. Adults 65 and older should get a second updated dose 6 months later. Children 6 to 23 months should be vaccinated against COVID-19; ages 2 to 18 follow a risk-based dose, and the academy supports access if a family wants the shot. Pregnancy, any trimester, and lactation are included. Flu vaccination starts at 6 months. RSV is a one-time adult shot at 75 and older, and at 50 to 74 for people at higher risk.

Pediatricians match the young-child COVID line and keep annual flu shots from 6 months up. They also widened second-season RSV protection for high-risk children 8 to 19 months, including those born before 32 weeks. Infectious-disease specialists separately call for COVID-19 vaccination for people 6 months and older with weak immune systems. That is not a federal order. It is professional advice sitting next to a narrower product label.

A Narrower FDA Label for the Same COVID Vials

The Food and Drug Administration cleared updated COVID-19 shots in late August for everyone 65 and older, and for younger people with at least one condition that raises the risk of severe disease. Pfizer and BioNTech announced XFG-adapted COVID-19 vaccine approval on Aug. 27 for COMIRNATY in adults 65 and older and in people 5 through 64 with a high-risk condition, with shipping starting immediately. Moderna’s Spikevax starts at 6 months for the high-risk group; its lower-dose mNEXSPIKE starts at 12. Nuvaxovid, the protein shot from Novavax and Sanofi, also starts at 12 for people with a high-risk condition. All four target the XFG subvariant that dominated the prior season.

Pregnancy, asthma, diabetes, heart and lung disease, obesity, and several other diagnoses sit on the high-risk list, so many younger adults are inside the FDA indication. FDA officials have estimated that about 30% to 60% of Americans have a qualifying condition. Healthy adults under 65, and healthy kids outside the youngest band, are the mismatch: societies say yes, the label often says no unless a clinician stretches it.

FDA LABELS VERSUS SOCIETY ADVICE

Flu advice does not split the same way. The societies still want a flu shot for almost everyone 6 months and older, which tracks the long-running federal line the CDC has pointed clinics back to while it issues no new fall package. COVID-19 is where a pharmacist reading the vial can legally stop a healthy 40-year-old whom a family doctor just encouraged to roll up a sleeve.

Who Can Get a COVID Shot at a Pharmacy?

Most fall COVID-19 and flu doses are given in pharmacies, not in a pediatric or OB office. In many states a pharmacist’s authority still tracks an FDA indication, an ACIP vote, or a public-health standing order. With the federal advisory panel frozen, that third document is doing the work ACIP used to do, state by state, and chain websites have not all caught up.

Walgreens says the updated COVID-19 vaccine at pharmacies is on offer in most states for adults 65 and older and for younger people at higher risk. Arizona and Oregon are listed as prescription-only on that page. Arizona health officials confirmed on Sept. 5 that a statewide standing order, signed by department adviser and former Surgeon General Dr. Richard Carmona, lets pharmacists give the new formulas without an individual Rx, because state law otherwise ties pharmacy shots to a federal advisory recommendation that has not been voted this year. Oregon issued its own statewide order so licensed vaccinators can give 2026-27 COVID-19 shots, with pharmacists and technicians limited to patients 7 and older under their licenses, and with a list that includes young children, older adults, people with medical conditions, and those who choose the shot.

WHERE A PHARMACIST CAN GIVE THE SHOT

• Chain default: Walgreens is booking 2026-27 COVID-19 doses in most states for ages 65 and older and for younger people it treats as higher risk, with walk-in or app scheduling.
• Two-state flag: The same Walgreens page still tells Arizona and Oregon patients to bring a prescription, even after both states wrote standing orders.
• Arizona workaround: The Sept. 5 standing order exists because ACIP has not met to refresh the recommendation pharmacists there are trained to follow.
• Oregon workaround: The health officer’s order is the prescription, and it is written more broadly than the FDA label, including people who choose vaccination.
• Kids at the counter: Child age limits still vary by state license, so a toddler who is in the AAP COVID band may need a clinic, not a retail pharmacy.

Updated Moderna COVID-19 doses were already going into arms at Walgreens by the first weekend in September, with some patients booking flu shots for early October. Independent shops were advertising high-dose flu the same weekend. The argument on the sidewalk is no longer abstract. People are picking their clinician’s chart or the federal label, then finding out whether the person behind the glass can legally draw the dose.

Coverage After the March Court Freeze

Insurance is the other hidden gate. ACA-style plans have long had to cover ACIP-recommended shots in-network with no copay. Dorit Reiss, a vaccine-policy scholar at the University of California College of the Law, San Francisco, has noted that without a current ACIP recommendation, private insurers are not forced to pay. AHIP, the insurer trade group, said its members would cover the shots anyway through 2027. UnitedHealthcare, which is not in AHIP, said the same. Medicare still pays for flu and COVID-19 vaccines under Part B. Employer plans can still differ, which is why a front desk that quotes “free at the pharmacy” is guessing unless it checks the card.

That coverage habit was built on a committee that is not meeting. Health Secretary Robert F. Kennedy Jr. replaced ACIP’s sitting members in 2025. U.S. District Judge Brian Murphy in Massachusetts, ruling on March 16, 2026 in a suit led by the AAP and other medical groups, blocked those appointees from serving and froze votes that had narrowed childhood shots and COVID-19 advice. The Justice Department told the 1st Circuit the panel lacks a quorum to issue the annual flu recommendation. Flu already has a long-standing universal recommendation, which former CDC officials have said may not need a fresh vote. COVID-19 and new products are the ones left without a federal stamp pharmacies and plans are used to seeing.

HOW THE FEDERAL PANEL WENT DARK

1. December 2025: ACIP last meets under the reconstituted roster; it has not convened a regular recommendation session since.
2. January 2026: CDC leadership issues a childhood schedule that cuts routinely recommended diseases from 17 to 11, without the usual ACIP vote.
3. March 16, 2026: Judge Murphy blocks the Kennedy appointees and the narrowed schedule, restoring the prior childhood list for now.
4. June 2026: The administration asks the 1st Circuit to revive the panel, arguing it cannot complete the flu cycle without a quorum.
5. Aug. 5 and Aug. 27, 2026: FDA approves mFLUSIVA and the XFG COVID-19 shots while ACIP is still unable to vote on how to use them.
6. Sept. 2, 2026: The four societies and the Vaccine Integrity Project publish the advice and evidence reviews clinicians are using instead.

The societies cannot compel a plan or a board of pharmacy. They can only publish. States that want retail access have had to write standing orders. Insurers that want to avoid a fall fight have had to promise coverage they are not currently required to give.

Flu Vaccines Cut Hospital Risk 31% for Older Adults

Flu is the shot with the fewest paperwork fights, and the one with the hardest recent pediatric record. The CDC estimated about 45,000 U.S. flu deaths in the 2024-25 season, including at least 297 in children. The societies still want everyone 6 months and older, without a medical reason to skip, to get a flu vaccine approved for their age. October is the timing they prefer, because influenza usually starts spreading in November.

Adults 65 and older should try for an enhanced flu vaccine (high-dose, adjuvanted, recombinant, or the new mRNA shot) when it is on the shelf, Nosal said, and should not wait if that option is out. FluMist remains a needle-free choice for people 2 to 49 who meet the health rules. Moderna’s mFLUSIVA, approved Aug. 5, is the first mRNA flu vaccine, cleared for ages 50 and older (full approval at 50 to 64, accelerated approval at 65 and up). It is not approved in pregnancy.

WHAT THE 2026 EVIDENCE REVIEW FOUND

• Older adults, flu: Vaccination was tied to 31% fewer influenza hospitalizations in people 65 and older in VISION data from September 2025 to February 2026, the figure the Vaccine Integrity Project has been citing from its influenza vaccine effectiveness and safety review.
• Children, flu deaths: Across eight seasons, flu vaccination was 80% effective against laboratory-confirmed influenza deaths in ages 6 months to 17 years.
• Pregnancy, infants: Flu vaccination in pregnancy was associated with 44.4% fewer symptomatic flu cases in babies through 6 months.
• mFLUSIVA, relative benefit: In the phase 3 trial, mFLUSIVA had a 26.6% relative advantage against flu-like illness versus a standard-dose shot (411 cases among 20,179 recipients vs. 557 among 20,124).
• Older adults, COVID-19: Last season’s COVID-19 shots were tied to a 53% drop in hospitalization for ages 65 and older, and a 48% drop in emergency or urgent-care visits.

The shots still miss plenty of milder infections. The reviews found no new safety alarms in the comparative studies they screened, and they keep pointing at hospital beds and deaths rather than at a promise of zero colds. Common reactions remain a sore arm, tiredness, headache, muscle aches, and a short fever, and those showed up somewhat more often with mFLUSIVA than with standard flu shots.

RSV Shots in Pregnancy, Antibodies for Infants

RSV is still a cold for many adults and a hospital virus for babies and the oldest patients. Family physicians back a one-time RSV vaccine at 75 and older, and at 50 to 74 when risk is higher, plus a dose for immunocompromised adults and teens. They also back Abrysvo at 32 to 36 weeks of pregnancy from September through March. Infants under 8 months whose mothers were not vaccinated should get nirsevimab or clesrovimab. High-risk children 8 through 19 months entering a second RSV season should get nirsevimab.

ACOG stretched the pregnancy RSV window to March 1, from the old Jan. 31 cutoff, because recent seasons have run later and harder. Abrysvo remains the only RSV vaccine approved for pregnancy, and it is meant once, in the first eligible pregnancy, not repeated. If the pregnant patient misses it, the baby should get a monoclonal antibody at birth. Dr. Brenna Hughes, who led ACOG’s RSV advisory, said as many as 80,000 children under 5 are hospitalized with RSV in a year, with the highest rates in babies 6 months and younger. Uptake is still thin: 41.6% of eligible pregnant patients have received the maternal RSV shot.

COVID-19 vaccination in pregnancy is the other number that should bother clinics. ACOG says only 11.1% of pregnant women got a COVID-19 shot in the 2025-26 season, down 25.7% from the year before, with the lowest rates among Hispanic and Black pregnant patients. The college still recommends the shot for people who are pregnant, postpartum, lactating, or planning pregnancy, and says all four FDA-approved COVID-19 vaccines are considered safe in pregnancy. Dr. Mark Turrentine, lead author of that guidance, said it is well established that COVID-19 vaccination does not cause pregnancy loss, including in the first trimester, and that infection is the risk, especially with other health problems.

Vaccination is standard preventive care, and complications can occur in pregnancy as a result of not being vaccinated that are completely preventable.

Dr. Camille A. Clare, President, American College of Obstetricians and Gynecologists, Sept. 2, 2026 release

ACOG also notes that when the vials are in the office during the counseling visit, acceptance is 5 to 50 times higher than when the patient is sent somewhere else. That is the access problem in one statistic. A society PDF cannot stock an exam room or rewrite a pharmacy statute.

October Is Still the Best Month for a Flu Shot

Fryhofer has said a COVID-19 dose can be timed a few weeks before a trip or gathering a patient cannot afford to miss, because COVID-19 often rises in late summer and again after the winter holidays. Flu is the one that still maps to a calendar: get it in October, before November spread. The three shots can be given in one visit when the products are approved for that patient. mFLUSIVA stays off the pregnancy list. Nasal flu spray stays off the list for pregnancy and for people with weak immune systems.

The American Immunization Registry Association is turning the society recommendations into structured logic for immunization registries and electronic records, with that guidance expected by mid-September. Until software catches up, a pharmacist is still reading a label, a standing order, and a claim edit. Medicare and the large insurers that promised 2027 coverage will make the easy cases simple. Healthy adults under 65 who want a COVID-19 shot because their family doctor said so, and parents who want a dose for a toddler who is not high-risk, will keep testing whether the person with the refrigerator is allowed to say yes.

By the first days of September, the vials were already moving. The court case was not. The people who decide the next arm in line work behind a pharmacy counter, in a state health department, and at an insurer, not on the letterhead of the Sept. 2 chart.

Disclaimer: This article is news reporting on published vaccine advice, product labels, and access rules. It is informational only and is not medical advice, a diagnosis, or an order to vaccinate. It does not tell any reader which flu, COVID-19, or RSV product to receive, skip, or delay, and it is not a substitute for a personal recommendation. Talk with a licensed physician, pediatrician, obstetrician, or pharmacist who knows your history before you get a shot. Figures, labels, pharmacy policies, and insurance rules reflect the cited statements on the dates named above and can change.